KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia.

Bin Jiang, Jian Li, Ligen Liu, Xin Du, Hao Jiang, Jianda Hu, Xiaoxi Zeng, Taishi Sakatani, Masanori Kosako, Yaru Deng, Larisa Girshova, Sergey Bondarenko, Lily Wong Lee Lee, Archrob Khuhapinant, Elena Martynova, Nahla Hasabou, Jianxiang Wang

Ann Hematol 104(3) 1563-1575

PMID40063243
PMCIDPMC12031924
DOI10.1007/s00277-025-06235-y
发表日期2025-03-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。
摘要

摘要

The COMMODORE study demonstrated the efficacy and safety of gilteritinib versus salvage chemotherapy (SC) treatment in a predominantly Asian population with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-mutated(mut+) acute myeloid leukemia (AML); here we present an exploratory analysis of the study stratified by region (China, South-East Asia and Russia). COMMODORE was a Phase 3, open-label, randomized (1:1), multicenter trial. There were 151, 50, and 33 patients in the China, South-East Asia, and Russia cohorts, respectively. Patients treated with gilteritinib had prolonged median overall survival (OS) versus SC-treated patients in all regions (China: 10.0 vs. 5.7 months, HR [95% CI]: 0.614 [0.385, 0.981]; South-East Asia: 7.8 vs. 4.7 months, HR [95% CI]: 0.887 [0.427, 1.843]; Russia: 8.8 vs. 2.6 months, HR [95% CI]: 0.271 [0.111, 0.662]). Improvements in event-free survival (EFS) were observed in the gilteritinib versus SC arms across all cohorts (China: 2.1 vs. 0.8 months; HR [95% CI]: 0.645 [0.427, 0.974]; South-East Asia 2.4 vs. < 0.1 months; HR [95% CI]: 0.415 [0.208, 0.830]; Russia: 6.2 vs. 0.6 months; HR [95% CI]: 0.221 [0.080, 0.614]). Complete remission rates were numerically higher in the gilteritinib versus SC arm across all three regions. Gilteritinib compared with SC treatment improved OS and EFS with no new safety signals, reinforcing the known efficacy and safety profile of gilteritinib in patients with R/R FLT3mut+ AML, and affirming the clinical benefit of gilteritinib in three different patient populations. ClinicalTrials.gov identifier: NCT03182244.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Kaplan–Meier estimates of ( A ) overall survival and ( B ) event-free survival in the China cohort (N = 151). P-values were calculated from the unstratified 2-side log-rank test. P-values should be considered nominal. HRs were based on the Cox proportional hazards model. Assuming proportional hazards, an HR < 1 indicates a reduction in hazard rate in favor of the treatment arm. CI, confidence interval; HR, hazard ratio; NE, not estimable; SC, salvage chemotherapy
非 KM Figure
Fig. 2Kaplan–Meier estimates of ( A ) overall survival and ( B ) event-free survival in the South-East Asia cohort (N = 50). P-values were calculated from the unstratified 2-side log-rank test. P-values should be considered nominal. HRs were based on the Cox proportional hazards model. Assuming proportional hazards, an HR < 1 indicates a reduction in hazard rate in favor of the treatment arm. CI, confidence interval; HR, hazard ratio; NE, not estimable; SC, salvage chemotherapy
非 KM Figure
Fig. 3Kaplan–Meier estimates of ( A ) overall survival and ( B ) event-free survival in the Russia cohort (N = 33). P-values were calculated from the unstratified 2-side log-rank test. P-values should be considered nominal. HRs were based on the Cox proportional hazards model. Assuming proportional hazards, an HR < 1 indicates a reduction in hazard rate in favor of the treatment arm. CI, confidence interval; HR, hazard ratio; NE, not estimable; SC, salvage chemotherapy
非 KM Figure